{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:42:35Z","timestamp":1791754955499,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Disturbances of glucose metabolism can be diagnosed by an oral glucose tolerance test (OGTT) and by glycated haemoglobin (HbA1c). The aim of this study was to investigate the association between newly detected disturbances of glucose metabolism and long-term prognosis after acute myocardial infarction (AMI) and to compare the predictive value of an OGTT and HbA1c.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients under the age of 80\u00a0years with no known history of diabetes admitted for AMI at the Department of Cardiology, Danderyd University Hospital, Stockholm, Sweden, from January 1st, 2006 until December 31st, 2013, were investigated with an OGTT and a HbA1c before discharge and were classified as having normal glucose tolerance (NGT), prediabetes or diabetes according to American Diabetes Association (ADA) criteria. Using nationwide, all-inclusive registers, patients were followed for the incidence of combined event [CE (first of myocardial infarction, heart failure, ischaemic stroke or mortality)] for a mean follow-up time of 4.8\u00a0years. Cox regression analysis was used to calculate Hazard Ratios (HR) and their 95% confidence intervals (CI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 841 patients who were investigated with both an OGTT and a HbA1c, 139 (17%) patients had NGT, 398 (47%) had prediabetes and 304 (36%) had diabetes according to OGTT. The corresponding figures using HbA1c were 320 (38%), 461 (55%) and 60 (7%). Patients with newly discovered diabetes were older and had a higher body mass index compared to those with NGT. OGTT was not predictive for CE. In contrast, prediabetes identified by a HbA1c was associated with an increased risk for CE (HR 1.31; 95% CI 1.05\u20131.63) compared to normoglycaemia. When comparing the prognostic value of different glucose and HbA1c cut-offs, only a HbA1c\u2009\u2265\u200939\u00a0mmol\/mol was significantly associated with CE (HR 95% CI; 1.30:1.05\u20131.61).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this single-centre study, in a recent contemporary cohort, we found that around two thirds of the patients admitted with AMI with no known history of diabetes had disturbed glucose metabolism, in accordance with previous studies. HbA1c in the prediabetes range, but not OGTT, added predictive value on the long-term outcome, in a cohort to whom a pathologic OGTT result was communicated with lifestyle advice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-021-01315-5","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T15:03:18Z","timestamp":1623682998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Long-term prognosis in patients with acute myocardial infarction and newly detected glucose abnormalities: predictive value of oral glucose tolerance test and HbA1c"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7826-1302","authenticated-orcid":false,"given":"Stelios","family":"Karayiannides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Djupsj\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Kuhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes","family":"Hofman-Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Norhammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Holzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Lundman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"key":"1315_CR1","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/S0735-1097(99)00387-3","volume":"34","author":"SM Grundy","year":"1999","unstructured":"Grundy SM, Pasternak R, Greenland P, et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. J Am Coll Cardiol. 1999;34:1348\u201359.","journal-title":"J Am Coll Cardiol"},{"key":"1315_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2337\/diacare.29.01.06.dc05-1405","volume":"29","author":"EJ Brunner","year":"2005","unstructured":"Brunner EJ, Shipley MJ, Witte DR, et al. Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care. 2005;29:26\u201331.","journal-title":"Diabetes Care"},{"key":"1315_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/2047487317709554","volume":"24","author":"A Norhammar","year":"2017","unstructured":"Norhammar A, Mellbin L, Cosentino F. Diabetes: prevalence, prognosis and management of a potent cardiovascular risk factor. Eur J Prev Cardiol. 2017;24:52\u201360.","journal-title":"Eur J Prev Cardiol"},{"key":"1315_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/1479164114551746","volume":"12","author":"V Ritsinger","year":"2014","unstructured":"Ritsinger V, Tanoglidi E, Malmberg K, et al. Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. Diabetes Vasc Dis Re. 2014;12:23\u201332.","journal-title":"Diabetes Vasc Dis Re"},{"key":"1315_CR5","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1136\/hrt.2004.052845","volume":"91","author":"R Otten","year":"2005","unstructured":"Otten R, Kline-Rogers E, Meier DJ, et al. Impact of pre-diabetic state on clinical outcomes in patients with acute coronary syndrome. Heart. 2005;91:1466.","journal-title":"Heart"},{"key":"1315_CR6","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/j.ehj.2004.09.021","volume":"25","author":"M Bartnik","year":"2004","unstructured":"Bartnik M, Malmberg K, Norhammar A, et al. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J. 2004;25:1990\u20137.","journal-title":"Eur Heart J"},{"key":"1315_CR7","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"ERF Collaboration","year":"2010","unstructured":"Collaboration ERF, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215\u201322.","journal-title":"Lancet"},{"key":"1315_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","volume":"15","author":"KGMM Alberti","year":"1998","unstructured":"Alberti KGMM, Zimmet PZ, Consultation W. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabetic Med. 1998;15:539\u201353.","journal-title":"Diabetic Med"},{"key":"1315_CR9","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2337\/dc09-9033","volume":"32","author":"Committee TIE","year":"2009","unstructured":"Committee TIE. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care. 2009;32:1327\u201334.","journal-title":"Diabetes Care"},{"key":"1315_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrendo.2016.105","volume":"12","author":"P Zimmet","year":"2016","unstructured":"Zimmet P, Alberti KG, Magliano DJ, et al. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nat Rev Endocrinol. 2016;12:616\u201322.","journal-title":"Nat Rev Endocrinol"},{"key":"1315_CR11","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/S2213-8587(15)00129-1","volume":"3","author":"G Danaei","year":"2015","unstructured":"Danaei G, Fahimi S, Lu Y, et al. Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331 288 participants. Lancet Diabetes Endocrinol. 2015;3:624\u201337.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1315_CR12","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1093\/eurheartj\/ehv008","volume":"36","author":"V Gyberg","year":"2015","unstructured":"Gyberg V, Bacquer DD, Kotseva K, et al. Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV\u2014a survey from the European Society of Cardiology. Eur Heart J. 2015;36:1171\u20137.","journal-title":"Eur Heart J"},{"key":"1315_CR13","doi-asserted-by":"publisher","first-page":"dc170245","DOI":"10.2337\/dc17-0245","volume":"40","author":"B Shahim","year":"2017","unstructured":"Shahim B, Bacquer DD, Backer GD, et al. The prognostic value of fasting plasma glucose, two-hour postload glucose, and HbA1c in patients with coronary artery disease: a report from EUROASPIRE IV. Diabetes Care. 2017;40:dc170245.","journal-title":"Diabetes Care"},{"key":"1315_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00125-004-1334-6","volume":"47","author":"T Nakagami","year":"2004","unstructured":"Nakagami T, Group DS. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004;47:385\u201394.","journal-title":"Diabetologia"},{"key":"1315_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2019","unstructured":"Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDThe Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2019;41:255\u2013323.","journal-title":"Eur Heart J"},{"key":"1315_CR16","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1016\/S0140-6736(02)09089-X","volume":"359","author":"A Norhammar","year":"2002","unstructured":"Norhammar A, Tenerz \u00c5, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140\u20134.","journal-title":"Lancet"},{"key":"1315_CR17","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1136\/hrt.2010.198804","volume":"96","author":"T Jernberg","year":"2010","unstructured":"Jernberg T, Attebring MF, Hambraeus K, et al. The Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart. 2010;96:1617.","journal-title":"Heart"},{"key":"1315_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","volume":"24","author":"JF Ludvigsson","year":"2009","unstructured":"Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24:659\u201367.","journal-title":"Eur J Epidemiol"},{"key":"1315_CR19","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.2337\/dc21-S002","volume":"44","author":"AD Association","year":"2020","unstructured":"Association AD. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes\u20142021. Diabetes Care. 2020;44:S15\u201333.","journal-title":"Diabetes Care"},{"key":"1315_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2047487319878371","volume":"26","author":"ED Canto","year":"2019","unstructured":"Canto ED, Ceriello A, Ryd\u00e9n L, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26:25\u201332.","journal-title":"Eur J Prev Cardiol"},{"key":"1315_CR21","doi-asserted-by":"crossref","first-page":"147916412097367","DOI":"10.1177\/1479164120973676","volume":"17","author":"V Ritsinger","year":"2020","unstructured":"Ritsinger V, Lagerqvist B, Lundman P, et al. Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry. Diabetes Vasc Dis Re. 2020;17:1479164120973676.","journal-title":"Diabetes Vasc Dis Re"},{"key":"1315_CR22","unstructured":"OECD. Health at a Glance 2019, https:\/\/www.oecd-ilibrary.org\/content\/publication\/4dd50c09-en (2019)."},{"key":"1315_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/hrt.2005.086975","volume":"93","author":"M Bartnik","year":"2007","unstructured":"Bartnik M, Ryd\u00e9n L, Malmberg K, et al. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. Heart. 2007;93:72.","journal-title":"Heart"},{"key":"1315_CR24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12933-020-01182-6","volume":"19","author":"K Matz","year":"2020","unstructured":"Matz K, Tuomilehto J, Teuschl Y, et al. Comparison of oral glucose tolerance test and HbA1c in detection of disorders of glucose metabolism in patients with acute stroke. Cardiovasc Diabetol. 2020;19:204.","journal-title":"Cardiovasc Diabetol"},{"key":"1315_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/cen.14043","volume":"91","author":"K Chatzianagnostou","year":"2019","unstructured":"Chatzianagnostou K, Vigna L, Piazza SD, et al. Low concordance between HbA1c and OGTT to diagnose prediabetes and diabetes in overweight or obesity. Clin Endocrinol. 2019;91:411\u20136.","journal-title":"Clin Endocrinol"},{"key":"1315_CR26","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1056\/NEJMoa0908359","volume":"362","author":"E Selvin","year":"2010","unstructured":"Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. New Engl J Med. 2010;362:800\u201311.","journal-title":"New Engl J Med"},{"key":"1315_CR27","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1093\/eurheartj\/ehy233","volume":"39","author":"S Chattopadhyay","year":"2018","unstructured":"Chattopadhyay S, George A, John J, et al. Adjustment of the GRACE score by 2-hour post-load glucose improves prediction of long-term major adverse cardiac events in acute coronary syndrome in patients without known diabetes. Eur Heart J. 2018;39:2740\u20135.","journal-title":"Eur Heart J"},{"key":"1315_CR28","doi-asserted-by":"crossref","unstructured":"Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Diabetes Res Clin Pr 2011; 93: 299\u2013309.","DOI":"10.1016\/j.diabres.2011.03.012"},{"key":"1315_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.","journal-title":"BMC Public Health"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01315-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-021-01315-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01315-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T15:03:46Z","timestamp":1623683026000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-021-01315-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1315"],"URL":"https:\/\/doi.org\/10.1186\/s12933-021-01315-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"assertion":[{"value":"28 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the regional research ethics committee in Stockholm, Sweden (reg. no 2014\/338-31\/2 and 2018\/1321-32).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest concerning this study. Dr. Karayiannides reports personal fees from Astra Zeneca, Boehringer Ingelheim and Novo Nordisk, outside the submitted work. Dr. Djupsj\u00f6, Dr. Kuhl and Dr. Hofman-Bang have nothing to disclose. Prof. Norhammar reports personal fees from Astra Zeneca, MSD, Boehringer Ingelheim, Lilly and Novo Nordisk, outside the submitted work. Prof. Holzmann reports personal fees from Idorsia, outside the submitted work. Dr. Lundman reports personal fees from Boehringer Ingelheim, Sanofi and Novo Nordisk, outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"122"}}